Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $37.71 USD
Change Today +0.25 / 0.67%
Volume 298.1K
FLDM On Other Exchanges
As of 8:10 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

fluidigm corp (FLDM) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/20/15 - $46.38
52 Week Low
10/13/14 - $21.71
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for FLUIDIGM CORP (FLDM)

Related News

No related news articles were found.

fluidigm corp (FLDM) Related Businessweek News

No Related Businessweek News Found

fluidigm corp (FLDM) Details

Fluidigm Corporation creates, manufactures, and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics. It provides various preparatory instruments, including C1 single-cell auto prep system, a sample preparation system that isolates, processes, and profiles individual cells for genomic analysis; and access array systems that enables automated polymerase chain reaction (PCR)-based target enrichment, barcoding, and tagging of resequencing libraries and facilitates parallel amplification. The company also offers analytical instruments comprising Biomark HD system, a PCR analytical instrument for gene expression analysis, single-cell targeted gene expression analysis, microRNA analysis, single nucleotide polymorphism (SNP) genotyping, and digital PCR; EP1 system that performs high-throughput SNP genotyping and end-point digital PCR; and CyTOF 2 system, a mass cytometry instrument that performs single-cell protein analysis by analyzing cells labeled with a panel of reagents conjugated to stable metal isotopes. In addition, it provides integrated fluidic circuits (IFCs), such as C1, access array, dynamic array, digital array, and flex six IFCs; assays and reagents consisting of Delta Gene and SNP type assays, access array target-specific primers, and Maxpar Reagents. Further, the company’s products include juno systems and IFCs, callisto systems and IFCs, polaris systems and IFCs, and C1 mRNA Sequencing IFCs. It serves academic institutions; clinical laboratories; and pharmaceutical, biotechnology, and agricultural biotechnology companies. The company distributes its products through direct sales force and support organizations, distributors, or sales agents. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.

474 Employees
Last Reported Date: 02/26/15
Founded in 1999

fluidigm corp (FLDM) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $490.0K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $320.0K
Chief Operating Officer
Total Annual Compensation: $325.0K
Executive Vice President of Legal Affairs, Ge...
Total Annual Compensation: $325.0K
Executive Vice President of Research & Develo...
Total Annual Compensation: $320.0K
Compensation as of Fiscal Year 2014.

fluidigm corp (FLDM) Key Developments

Fluidigm Corporation Debuts Newest Single-Cell System at AGBT

Fluidigm Corporation will provide attendees at the 16th annual Advances in Genome Biology and Technology (AGBT) meeting the first glimpse of PolarisTM, an integrated single-cell research system, in addition to other new products. This exciting new product is the first to integrate cell selection, isolation, dose, culture and molecular preparation into a single workflow, thereby enabling researchers to directly correlate gene expression with environmental conditions and phenotypic information. With this new workflow, researchers will be able to conduct dose-response and time course studies on live, single cells to identify interesting genes that regulate critical pathways, as well as better evaluate the diversity of biological effects across cell types. The Polaris system will consist of new instrumentation and a new class of Fluidigm integrated fluidic circuits (IFCs), which allow reagent dosing and cell culture experiments at the single-cell level. These new IFCs will include the processing of single cells for downstream molecular biology preparatory and analysis techniques. Data generated by the Polaris system will be processed using Fluidigm's Singular Analysis Toolset, which includes features to filter, visualize and identify biologically relevant genes and variants. Fluidigm will also showcase how its new single-cell biology and production genomics platforms can come together to create the ideal lab.

Fluidigm Corporation Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Earnings Guidance for the Full Year 2015

Fluidigm Corporation reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, total revenue was $33.5 million, an increase of 60% from $20.9 million in the fourth quarter of 2013. Net loss was $10.9 million or $0.39 per basic and diluted share compared to a net loss of $4.6 million or $0.18 per basic and diluted share in the fourth quarter of 2013. Non-GAAP net loss was $1.7 million, compared with a $1.9 million non-GAAP net loss for the fourth quarter of 2013. Loss from operations was $9.83 million compared to $4.64 million a year ago. Loss before income taxes was $11.83 million compared to $4.60 million a year ago. Net cash used in operating activities, excluding cash outflows related to the acquisition, was $14.6 million in 2014 versus $1.6 million in 2013. For the full year. total revenue was $116.5 million, an increase of 64% from $71.2 million in 2013. Net loss was $52.8 million or $1.90 per basic and diluted share compared to a net loss of $16.5 million or $0.65 per basic and diluted share in 2013. Non-GAAP net loss for the full year of 2014 was $6.4 million, compared with $8.5 million non-GAAP net loss for the full year of 2013. Loss from operations was $51.84 million compared to $18.65 million a year ago. Loss before income taxes was $57.71 million compared to $16.39 million a year ago. Net cash used in operating activities was $22.62 million compared to $1.59 million a year ago. Purchases of property and equipment was $7.40 million compared to $3.45 million a year ago. The company provided earnings guidance for the full year 2015. The company projects total revenue for the full year 2015 to be between $142 million and $149 million. 2015 revenue projections incorporate an estimated negative currency related impact of approximately 3% to 4% at the midpoint of the range. The company projects 2015 $5 million of depreciation and amortization expense. Interest expense is projected to be approximately $6 million and capital spending is projected to be between $6 and $9 million.

Fluidigm Corporation to Report Q4, 2014 Results on Feb 05, 2015

Fluidigm Corporation announced that they will report Q4, 2014 results at 2:00 PM, Pacific Standard Time on Feb 05, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FLDM:US $37.71 USD +0.25

FLDM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Affymetrix Inc $12.17 USD +0.04
Biotage AB kr16.40 SEK 0.00
Luminex Corp $15.84 USD +0.32
NanoString Technologies Inc $12.67 USD +0.73
Pacific Biosciences of California Inc $5.67 USD +0.51
View Industry Companies

Industry Analysis


Industry Average

Valuation FLDM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.1x
Price/Book 7.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FLUIDIGM CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at